Accessibility Statement Skip Navigation
  • Back to Global Sites
  • +972-77-2005042
  • Blog
  • Journalists
  • GDPR
  • Send a Release
PR Newswire: news distribution, targeting and monitoring
  • News
  • Products
  • Contact
  • Hamburger menu
  • PR Newswire: news distribution, targeting and monitoring
  • Send a Release
    • Telephone

    • +972-77-2005042 from 8 AM - 11 PM IL

    • Contact
    • Contact

      +972-77-2005042
      from 8 AM - 11 PM IL

  • When typing in this field, a list of search results will appear and be automatically updated as you type.

  • Request More Information
  • Journalists
  • GDPR
  • Request More Information
  • Journalists
  • GDPR
  • Request More Information
  • Journalists
  • GDPR
  • Request More Information
  • Journalists
  • GDPR

The EVA System Colposcope Fulfills Promise of the AVE Algorithm to Change Future of Cervical Cancer Detection

MobileODT, first to develop a commercial application for AVE machine learning algorithm for cervical cancer detection


News provided by

MobileODT

11 Jan, 2019, 17:16 IST

Share this article

Share toX

Share this article

Share toX

TEL AVIV, Israel, January 11, 2019 /PRNewswire/ --

A new augmented intelligence (AI) algorithm is able to detect cervical cancer based on a single image. Automated Visual Evaluation (AVE) is an exciting breakthrough already being brought to clinical use with MobileODT's EVA System Colposcope.

Validated by the National Cancer Institute and National Library of Medicine, the AVE machine learning algorithm is able to identify problematic lesions with greater reliability than traditional Pap Cytology testing. When the same images were presented to an expert human colposcopist, the algorithm had a higher level of accuracy.

For this new technology to move out of the laboratory and into healthcare practice, a practical application was needed. The EVA System is the only colposcope on the market ready to deliver AVE at the point-of-care. "We are excited by the new AVE algorithm and the promise it holds in fighting cervical cancer. Our team is proud to make available an AVE enabled colposcope to reach more women and save more lives," says Ariel Beery, MobileODT CEO.

MobileODT is working with the NCI and other researchers to further validate the initial AVE algorithm to bring this lifesaving technology to patients quickly, continuously improving the algorithm performance with new data collected from global research partners, proving one does not need special conditions or expertise to use the power of AI.

The EVA Colposcope is a mobile digital colposcope currently in 29 countries and 50 US healthcare systems. Using smartphone technology, it is designed to go wherever women are to ensure that no woman dies of a preventable disease. Adding AI cervical cancer detection to the EVA System was the obvious next step.

Early this week, MobileODT announced a large scale pilot to validate the clinical application of the AVE algorithm with partners Genworks Health and Apollo Hospitals in India. The clinical study to be conducted will improve the AI algorithm used in cervical cancer detection by evaluating the algorithm performance. This represents the first wide-scale validation of the algorithm on the EVA System, screening up to 250 women daily.

About MobileODT 
MobileODT is reimagining medical visualization technology to enhance women's health. Combining advanced imaging, data and software applications, Mobile ODT is saving lives by enabling early cancer detection.

Contact: +1-929-376-0061

SOURCE MobileODT

Modal title

Contact PR Newswire

  • +972-77-2005042
    from 8 AM - 11 PM IL

Global Sites

  • APAC
  • APAC - Traditional Chinese
  • Asia
  • Brazil
  • Canada
  • Czech
  • Denmark
  • Finland
  • France
  • Germany

 

  • India
  • Indonesia
  • Israel
  • Italy
  • Mexico
  • Middle East
  • Middle East - Arabic
  • Netherlands
  • Norway
  • Poland

 

  • Portugal
  • Russia
  • Slovakia
  • Spain
  • Sweden
  • United Kingdom
  • United States

Do not sell or share my personal information:

  • Submit via [email protected] 
  • Call Privacy toll-free: 877-297-8921
Global Sites
  • Asia
  • Brazil
  • Canada
  • Csezh
  • Denmark
  • Finland
  • France
  • Germany
  • India
  • Israel
  • Italie
  • Mexico
  • Middle East
  • Netherlands
  • Norway
  • Poland
  • Portugal
  • Russia
  • Slovakia
  • Spain
  • Sweden
  • United Kingdom
  • United States
+972-77-2005042
from 8 AM - 11 PM IL
  • Terms of Use
  • Privacy Policy
  • Information Security Policy
  • Site Map
  • Cookie Settings
Copyright © 2026 Cision US Inc.